Tekmira Pharmaceuticals said this week that it has acquired an exclusive, worldwide license to an RNAi technology developed by Halo-Bio RNAi Therapeutics.
The technology, called multivalent RNAi, comprises “single macromolecules capable of mediating RNAi at multiple unique target sites,” Tekmira said. “MV-RNA can target three sites on a single gene or up to three separate genes simultaneously.”
Tekmira said that it aims to combine the molecules with its proprietary lipid nanoparticles to develop therapeutics.
Financial terms of the arrangement were not disclosed.